User login
Key clinical point: Patients with relapsing-remitting multiple sclerosis (RRMS) having poor prognostic factors at baseline who were initiated with induction therapy have a lower risk for disability in the long term.
Major finding: After propensity matching, the proportion of patients reaching the primary outcome (Expanded Disability Status Scale [EDSS], ≥6.0) was lower in the induction group (28.0%) than the escalation group (38.7%). The median final EDSS scores were 5.0 and 4.5 after escalation and induction, respectively (P less than .001).
Study details: This study evaluated the long-term effectiveness of initial treatment with induction (n=75) or escalation (n=738) approach in patients with RRMS identified from a multicenter, retrospective registry database in Italy.
Disclosures: The authors declared no conflicts of interest.
Citation: Prosperini et al. Neurotherapeutics. 2020 Mar 31. doi: 10.1007/s13311-020-00847-0.
Key clinical point: Patients with relapsing-remitting multiple sclerosis (RRMS) having poor prognostic factors at baseline who were initiated with induction therapy have a lower risk for disability in the long term.
Major finding: After propensity matching, the proportion of patients reaching the primary outcome (Expanded Disability Status Scale [EDSS], ≥6.0) was lower in the induction group (28.0%) than the escalation group (38.7%). The median final EDSS scores were 5.0 and 4.5 after escalation and induction, respectively (P less than .001).
Study details: This study evaluated the long-term effectiveness of initial treatment with induction (n=75) or escalation (n=738) approach in patients with RRMS identified from a multicenter, retrospective registry database in Italy.
Disclosures: The authors declared no conflicts of interest.
Citation: Prosperini et al. Neurotherapeutics. 2020 Mar 31. doi: 10.1007/s13311-020-00847-0.
Key clinical point: Patients with relapsing-remitting multiple sclerosis (RRMS) having poor prognostic factors at baseline who were initiated with induction therapy have a lower risk for disability in the long term.
Major finding: After propensity matching, the proportion of patients reaching the primary outcome (Expanded Disability Status Scale [EDSS], ≥6.0) was lower in the induction group (28.0%) than the escalation group (38.7%). The median final EDSS scores were 5.0 and 4.5 after escalation and induction, respectively (P less than .001).
Study details: This study evaluated the long-term effectiveness of initial treatment with induction (n=75) or escalation (n=738) approach in patients with RRMS identified from a multicenter, retrospective registry database in Italy.
Disclosures: The authors declared no conflicts of interest.
Citation: Prosperini et al. Neurotherapeutics. 2020 Mar 31. doi: 10.1007/s13311-020-00847-0.